BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iluvien regulatory update

FDA issued a complete response letter for an NDA from Alimera for Iluvien to treat diabetic macular edema (DME). The company said FDA did not request any additional clinical trials, but did ask for further analyses...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >